Cleveland Clinic Taussig Cancer Center

Clinical research site in Cleveland, Ohio · 9500 EUCLID AVE # C21, CLEVELAND, OH 44195-0001 · (216) 444-0522

Part of Cleveland Clinic

As of September 2026, 24 paid clinical trials are recruiting at Cleveland Clinic Taussig Cancer Center in Cleveland, Ohio. Active studies at this site cover conditions such as Glioma, Advanced Solid Tumor and Advanced or Metastatic Solid Tumors. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: September 1, 2026.

New trial at Cleveland Clinic Taussig Cancer Center? We'll email you when one opens.

Recruiting clinical trials at Cleveland Clinic Taussig Cancer Center (24)

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

for Transthyretin Amyloid Cardiomyopathy (ATTR CM)

61 locations incl. Phoenix

Sponsor: Novo Nordisk A/S

Sex: All·Age: 18+

Code: NCT07207811·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

for Melanoma

58 locations incl. Birmingham

Sponsor: Pfizer

Sex: All·Age: 16+

Code: NCT05538130·Phase 1·Recruiting·Listed Sep 2022

Apply to this trial

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

for Melanoma, Cutaneous Malignant

43 locations incl. Phoenix

Sponsor: Immatics US, Inc.

Sex: All·Age: 18+

Code: NCT06743126·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

for Acute Myeloid Leukemia

44 locations incl. Phoenix

Sponsor: Kura Oncology, Inc.

Sex: All·Age: 18+

Code: NCT05735184·Phase 1·Recruiting·Listed Feb 2023

Apply to this trial

A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

for Left Ventricular Systolic Dysfunction

22 locations incl. Aurora

Sponsor: Bayer

Sex: All·Age: Up to 18

Code: NCT07192952·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)

for PIK3CA-Related Overgrowth Spectrum (PROS)

22 locations incl. Phoenix

Sponsor: Relay Therapeutics, Inc.

Sex: All·Age: 2+

Code: NCT06789913·Phase 2·Recruiting·Listed Jan 2025

Apply to this trial

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

for Advanced Solid Tumor

18 locations incl. Phoenix

Sponsor: BioNTech SE

Sex: All·Age: 18+

Code: NCT07070232·Phase 1, Phase 2·Recruiting·Listed Jul 2025

Apply to this trial

A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction

for Left Ventricular Systolic Dysfunction

22 locations incl. Aurora

Sponsor: Bayer

Sex: All·Age: 6 Months - 17

Code: NCT07188805·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

for Multiple Myeloma

17 locations incl. San Francisco

Sponsor: K36 Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05651932·Phase 1·Recruiting·Listed Dec 2022

Apply to this trial

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

for Advanced Solid Tumors

9 locations incl. Birmingham

Sponsor: Bayer

Sex: All·Age: 18+

Code: NCT06760819·Phase 2·Recruiting·Listed Jan 2025

Apply to this trial

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

for Ovarian Cancer

13 locations incl. Newport Beach

Sponsor: NextCure, Inc.

Sex: All·Age: 18+

Code: NCT06774963·Phase 1·Recruiting·Listed Jan 2025

Apply to this trial

A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

for GIST

11 locations incl. Los Angeles

Sponsor: Deciphera Pharmaceuticals, LLC

Sex: All·Age: 18+

Code: NCT05957367·Phase 1, Phase 2·Recruiting·Listed Jul 2023

Apply to this trial

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

for Urothelial Carcinoma

9 locations incl. Orange

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT05562830·Phase 1, Phase 2·Recruiting·Listed Oct 2022

Apply to this trial

A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

for KRAS G12C Mutation

11 locations incl. Phoenix

Sponsor: Kumquat Biosciences Inc.

Sex: All·Age: 18+

Code: NCT06720987·Phase 1·Recruiting·Listed Dec 2024

Apply to this trial

A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

for Advanced Solid Tumor

13 locations incl. Phoenix

Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.

Sex: All·Age: 18+

Code: NCT06859762·Phase 1·Recruiting·Listed Mar 2025

Apply to this trial

A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors

for Solid Tumors, Adult

8 locations incl. Denver

Sponsor: Hutchmed

Sex: All·Age: 18+

Code: NCT07228247·Phase 1, Phase 2·Recruiting·Listed Nov 2025

Apply to this trial

Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors

for Solid Tumor

3 locations incl. Canton

Sponsor: Lamassu Bio Inc

Sex: All·Age: 18+

Code: NCT06578624·Phase 1, Phase 2·Recruiting·Listed Aug 2024

Apply to this trial

Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes

for Metastatic Ewing Sarcoma

20 locations incl. Birmingham

Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Sex: All·Age: 1+

Code: NCT07194044·Phase 1·Recruiting·Listed Sep 2025

Apply to this trial

Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery

for Neoadjuvant Treatment

4 locations incl. Ann Arbor

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18+

Code: NCT06959511·Phase 2·Recruiting·Listed May 2025

Apply to this trial

Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms

for Barrett Esophagus

5 locations incl. Aurora

Sponsor: Case Comprehensive Cancer Center

Sex: All·Age: 50+·Accepts healthy volunteers

Code: NCT06687603·Recruiting·Listed Nov 2024

Apply to this trial

I-DECIDE After Bronchiolitis Hospitalization

for Bronchiolitis Acute

56 locations incl. Birmingham

Sponsor: Seattle Children's Hospital

Sex: All·Age: 0 Months - 24 Months

Code: NCT07243652·Recruiting·Listed Nov 2025

Apply to this trial

Development of MRF for Characterization of Brain Tumors After Radiotherapy

for Brain Tumor

2 locations in Cleveland

Sponsor: Case Comprehensive Cancer Center

Sex: All·Age: 18 - 60·Accepts healthy volunteers

Code: NCT06101069·Recruiting·Listed Oct 2023

Apply to this trial

Sacituzumab Govitecan in Recurrent Glioblastoma

for Recurrent Glioblastoma

3 locations incl. Cleveland

Sponsor: The University of Texas Health Science Center at San Antonio

Sex: All·Age: 18+

Code: NCT04559230·Phase 2·Recruiting·Listed Sep 2020

Apply to this trial

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

for Bladder Urothelial Carcinoma

2 locations incl. Cleveland

Sponsor: Yuanquan Yang

Sex: All·Age: 18+

Code: NCT06263153·Phase 2·Recruiting·Listed Feb 2024

Apply to this trial

Get new-trial alerts for Cleveland Clinic Taussig Cancer Center

We'll email you whenever a new clinical trial starts recruiting at this research site in Cleveland, OH. Unsubscribe anytime.

More research sites in Cleveland

Cleveland Clinic (356 trials)
University Hospitals Cleveland Medical Center (155 trials)
Cleveland Clinic Foundation (142 trials)
Case Western Reserve University (79 trials)
MetroHealth Medical Center (37 trials)
The Cleveland Clinic Foundation (27 trials)
Rainbow Babies and Childrens Hospital (25 trials)
Louis Stokes VA Medical Center, Cleveland, OH (24 trials)
Cleveland Clinic Main Campus (19 trials)
The Cleveland Clinic (17 trials)

Is this your research site?

This page is built from public ClinicalTrials.gov records. If you work here, we can correct it, send you the patients who apply, and build you a free website from your real studies — verify it with your work email, or read what we do for research sites.

Explore more

Paid clinical trials in Cleveland, OH · Ohio clinical trials